SCHEMBL968029

SCHEMBL968029

COc1c(C)cccc1-c1nc(N(C)Cc2c(C)cccc2-c2nc(N(C)C)c3ccccc3n2)c2ccccc2n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 14/20 0.59
CYP2D6 P10635 13/20 0.59
TSHR P16473 9/20 0.59
CYP2C19 P33261 9/20 0.59
CLK4 Q9HAZ1 7/20 0.59
MAPK1 P28482 2/20 0.59
CYP3A4 P08684 11/20 0.56
LMNA P02545 6/20 0.56
ALDH1A1 P00352 6/20 0.56
HSD17B10 Q99714 5/20 0.56
USP2 O75604 4/20 0.56
ALOX15 P16050 4/20 0.56
TP53 P04637 2/20 0.56
PDE5A O76074 1/20 0.48
CYP2C9 P11712 5/20 0.47
MAPT P10636 7/20 0.44
KDM4E B2RXH2 4/20 0.44
GBA1 P04062 3/20 0.44
HPGD P15428 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1084997 0.89 CYP2D6 (0.74) CYP1A2CYP2D6TSHRCYP2C19CLK4
SCHEMBL968028 0.77 CYP2D6 (0.57) CYP1A2CYP2D6TSHRCYP2C19CLK4
SCHEMBL937311 0.73 CYP2D6 (0.76) CYP1A2CYP2D6TSHRCYP2C19CLK4
SCHEMBL938193 0.72 CYP1A2 (1.00) CYP1A2CYP2D6TSHRCYP2C19CLK4
SCHEMBL963568 0.71 CYP1A2 (0.60) CYP1A2CYP2D6TSHRCYP2C19CLK4
SCHEMBL939163 0.68 CYP2D6 (0.74) CYP1A2CYP2D6TSHRCYP2C19CLK4
SCHEMBL937501 0.67 CYP2D6 (0.70) CYP1A2CYP2D6TSHRCYP2C19CLK4
SCHEMBL1084245 0.67 CYP2D6 (0.70) CYP1A2CYP2D6TSHRCYP2C19CLK4
SCHEMBL1083911 0.67 CYP2D6 (0.70) CYP1A2CYP2D6TSHRCYP2C19CLK4
SCHEMBL1083829 0.67 CYP2D6 (0.70) CYP1A2CYP2D6TSHRCYP2C19CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8343980-B2 Quinazoles useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-01-01 US disclosed
US-8153642-B2 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-04-10 US disclosed
US-20110021495-A1 QUINAZOLES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-27 US disclosed
US-20100160316-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-06-24 US disclosed
US-7713983-B2 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-05-11 US disclosed
US-7678802-B2 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-03-16 US disclosed
EP-1608632-B1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMA (US) 2009-12-30 EP disclosed
US-20060217377-A1 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2006-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160316-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS KCNN3, KCNN2, CACNA1I CYP1A2 2515/4885CYP2D6 2468/4885TSHR 3915/4885
US-20110021495-A1 QUINAZOLES USEFUL AS MODULATORS OF ION CHANNELS KCNN3, CACNA1I, CACNA1B CYP1A2 1509/4885CYP2D6 1496/4885TSHR 4227/4885
US-20060217377-A1 Quinazolines useful as modulators of ion channels KCNN3, KCNN2, CACNA1I CYP1A2 2515/4885CYP2D6 2468/4885TSHR 3915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.